Skin health and disease最新文献

{"title":"Skin biology and ageing.","authors":"Abigail K Langton, Rachel E B Watson","doi":"10.1002/ski2.458","DOIUrl":"https://doi.org/10.1002/ski2.458","url":null,"abstract":"","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"4 6","pages":"e458"},"PeriodicalIF":0.0,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11608899/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142775329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A prospective, double-blinded, randomized head-to-head clinical trial of topical adapinoid (oleyl adapalenate) versus retinol.","authors":"Nhi Nguyen, Nasima Afzal, Mildred Min, Nabeel Ahmad, Laila Afzal, Waqas Burney, Cindy J Chambers, Raja K Sivamani","doi":"10.1002/ski2.469","DOIUrl":"https://doi.org/10.1002/ski2.469","url":null,"abstract":"<p><strong>Background: </strong>Retinoids, such as retinol, are widely investigated and utilized in skin care products as a treatment for photoaging but their use is limited by tolerability. Adapinoid (oleyl adapalenate, OA) is a novel third generation retinoid that is a pro-drug of adapalene, but there is little research on its effects on photoaging or its tolerability.</p><p><strong>Objectives: </strong>The purpose of this study is to compare the effects and tolerability of OA 0.5% to retinol 0.5% cream regarding visible signs of facial photoaging including facial wrinkles, fine lines and pigmentation.</p><p><strong>Methods: </strong>In this 12-week, double-blind, randomized clinical trial, 48 eligible participants were recruited and enroled from the Greater Sacramento region. The study consisted of a baseline and follow-up visits at weeks 4, 8 and 12. Participants were randomized to receive either topical OA 0.5% or retinol 0.5% for 12 weeks. The primary outcome was changes in the appearance of wrinkle severity at 12 weeks. Secondary outcome measures include changes in erythema, skin pigmentation, skin hydration and transepidermal water loss (TEWL).</p><p><strong>Results: </strong>OA improved wrinkle severity by 9.45% (<i>p</i> < 0.0001) at week 12, whereas retinol improved wrinkle severity by 4.11% (<i>p</i> < 0.001) compared to baseline. When comparing the two treatment groups at week 12, the OA group improved significantly more than the retinol group (<i>p</i> = 0.001). OA decreased pigment intensity at week 12 by 3.88% (<i>p</i> < 0.0001), whereas retinol decreased pigment intensity by 3.15% (<i>p</i> < 0.03) compared to baseline. OA-based improvement in pigment intensity at week 12 was not significantly different from retinol (<i>p</i> = 0.62). OA reduced facial erythema by 13.39% (<i>p</i> < 0.05) at week 12, whereas the retinol group did not have a significant change. OA use led to a 14.92% decrease in TEWL by week 12 (<i>p</i> = 0.07), whereas the retinol group had no significant change. OA was better tolerated than retinol when assessed at all follow-up visits.</p><p><strong>Conclusions: </strong>OA 0.5% is superior to retinol 0.5% in improving wrinkle severity and similar in improvement of pigment intensity. OA is better tolerated than retinol. Overall, the use of OA as a precursor to adapalene may be an effective method to improving the tolerability of retinoids while maintaining efficacy.</p><p><strong>Trial registration: </strong>This study was registered on www.clinicaltrials.gov (NCT05778760).</p>","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"4 6","pages":"e469"},"PeriodicalIF":0.0,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11608876/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142775340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A retrospective single-institute study reveals a vertical gradient of the density of cutaneous melanoma from head to toe.","authors":"Meryl Musicante, James Ferrer, Jianjian Lin, Tejesh Surendr Patel, Feng Liu-Smith","doi":"10.1002/ski2.463","DOIUrl":"https://doi.org/10.1002/ski2.463","url":null,"abstract":"<p><strong>Background: </strong>The bodily distribution of melanoma is frequently reported without consideration of the skin surface area, which could be misleading in melanoma risk regarding anatomical sites.</p><p><strong>Objectives: </strong>To gain insights into the melanoma distribution on the body surface when the body surface area is considered.</p><p><strong>Methods: </strong>Cutaneous melanoma data were extracted from a single dermatopathology laboratory, and the relative density from each body site was calculated by taking into consideration the skin surface area. Data from a previous publication were analyzed as a validation. Surveillance, Epidemiology and End Results Program data were also used for comparison.</p><p><strong>Results: </strong>Relative tumour density (RTD) of melanoma in men and women exhibits a moderate head-to-toe linear gradient, with the upper body sites showing higher density than the lower body sites in general. In particular, the ear and face show the highest RTD while the least UVR (ultraviolet radiation)-exposed buttock, abdomen and groin have the lowest, followed by the thigh and lower legs. The trend is similar in both sexes, but more obvious for men.</p><p><strong>Conclusions: </strong>It was well documented that the trunk and lower legs are the most frequently diagnosed sites for men and women, respectively. However, when the surface area is considered, the melanoma distribution exhibits a rough head-to-toe gradient, which perhaps reflects a combined effect of solar UVR and clothing coverage. UVR protection on the face and ear should be emphasized as these are the sites with the highest RTDs.</p>","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"4 6","pages":"e463"},"PeriodicalIF":0.0,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11608879/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142775343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes in an educational skin-model session on point-of-care ultrasound for diagnosing calciphylaxis.","authors":"Max E Oscherwitz, Christopher T Kelly, Bridget Francis, Casey Glass, John R Edminister, Steven Feldman, Lindsay C Strowd","doi":"10.1002/ski2.467","DOIUrl":"https://doi.org/10.1002/ski2.467","url":null,"abstract":"","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"4 6","pages":"e467"},"PeriodicalIF":0.0,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11608863/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142775317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A cross-sectional study of the vulval dermatology clinic population over a 4-year period and development of a national vulval disease database.","authors":"Marianne de Brito, Lisa Kirby, Kate Lomas, Aysha Javed, Caroline Owen, Rosalind Simpson","doi":"10.1002/ski2.446","DOIUrl":"https://doi.org/10.1002/ski2.446","url":null,"abstract":"<p><strong>Background: </strong>Vulval disease significantly impacts quality of life but is historically under-researched. The epidemiology and aetiology of many vulval conditions is unclear. Data to optimise patient care are lacking.</p><p><strong>Objectives: </strong>To describe the population attending a specialist vulval dermatology clinic and achieve consensus amongst vulval experts on data items to be collected for a future national vulval database.</p><p><strong>Methods: </strong>This descriptive cross-sectional study analysed data that was prospectively collected during clinical contact with consecutive new patients at a vulval dermatology clinic over 4 years.A two-stage electronic-Delphi survey was performed with British vulval experts. Consensus was defined as ≥75% agreement on items for inclusion.</p><p><strong>Results: </strong>The database included 424 (including 29 paediatric) patients. Most patients were White British (71%), with a significant Asian population (13%). Long symptom duration (9.5% > 10 years) and multiple diagnoses, up to 4, were common. Exploratory associations were identified between irritant contact dermatitis and urinary and faecal incontinence, frequent vulval washing and lichen simplex, urinary incontinence and lichen sclerosus and a negative association between candidiasis and age.Following two rounds of the electronic-Delphi survey, consensus was achieved for 18 items that 28 participants agreed were important for a future database.</p><p><strong>Conclusions: </strong>We report disease incidence, patient pathways, outcome measures and potential associations. Though not generalisable, this large UK-based study could inform future projects to improve patient care and support ongoing research, such as a national vulval disease database, for which we also achieve expert consensus on the most valuable items to include.</p>","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"4 6","pages":"e446"},"PeriodicalIF":0.0,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11608872/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142775277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determining the minimal important change of the recap of atopic eczema (RECAP) instrument in clinical trials.","authors":"Arabella Baker, Beth Stuart, Laura Howells, Eleanor J Mitchell, Kim S Thomas","doi":"10.1002/ski2.470","DOIUrl":"https://doi.org/10.1002/ski2.470","url":null,"abstract":"<p><strong>Background: </strong>The Recap of atopic eczema (RECAP) is a patient-reported instrument designed to assess eczema control. There is a lack of evidence on the interpretability of change scores in clinical trials.</p><p><strong>Objectives: </strong>To calculate the smallest detectable change (SDC) in RECAP and estimate the minimal important change (MIC) for RECAP using various calculation methods in three eczema clinical trial datasets.</p><p><strong>Methods: </strong>In this study, four anchor-based methods (within-person score change, between-patient score change, predictive modelling, receiver operating characteristic curve) and a distribution-based method (effect size) was used to determine the MIC of RECAP. The trial datasets involved children (0-12 years), young people (13-25 years) and adults (>25 years) with all eczema severities.</p><p><strong>Results: </strong>A total of 698 participants were included in this study. The SDC was between 1.74 and 1.80. For the anchor-based methods, the patient global assessment anchor provided MIC values ranging from 2.35 to 3.94 and the patient oriented eczema measure anchor yielded values between 1.11 and 3.62. The MIC for the distribution-based method ranged from 2.66 to 3.06, respectively.</p><p><strong>Conclusions: </strong>The interpretability of RECAP was improved by establishing MIC values and the following thresholds are suggested for interpreting changes in RECAP scores: <2.0 points is possibly a measurement error; 2.0-2.9 points denotes a small improvement that may be clinically relevant; 3.0-3.9 points indicates an improvement that is likely to be clinically important and ≥4.0 points is highly likely to represent a clinically important change.</p>","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"4 6","pages":"e470"},"PeriodicalIF":0.0,"publicationDate":"2024-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11608894/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142775298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vascular endothelial growth factor A inhibition remodels the transcriptional signature of lipid metabolism in psoriasis non-lesional skin in 12 h ex vivo culture.","authors":"Andrea Luengas-Martinez, Dina Ismail, Ralf Paus, Helen S Young","doi":"10.1002/ski2.471","DOIUrl":"https://doi.org/10.1002/ski2.471","url":null,"abstract":"<p><strong>Background: </strong>Vascular endothelial growth factor A (VEGF-A)-mediated angiogenesis is involved in the pathogenesis of psoriasis. VEGF-A inhibitors are widely used to treat oncological and ophthalmological diseases but have not been used in psoriasis management. The molecular mechanisms underlying the effects of VEGF-A inhibition in psoriatic skin remain unknown.</p><p><strong>Objectives: </strong>To identify the genes and canonical pathways affected by VEGF-A inhibition in non-lesional and plaque skin ex vivo.</p><p><strong>Methods: </strong>Total RNA sequencing was performed on skin biopsies from patients with psoriasis (<i>n</i> = 6; plaque and non-lesional skin) and healthy controls (<i>n</i> = 6) incubated with anti-VEGF-A monoclonal antibody (bevacizumab, Avastin®) or human IgG₁ isotype control for 12 h in serum-free organ culture. Differentially expressed genes between paired control and treated samples with adjusted <i>p</i>-values <0.1 were considered significant. Gene ontology and ingenuity pathway analysis was used to identify enriched biological processes, canonical pathways and upstream regulators.</p><p><strong>Results: </strong>VEGF-A inhibition upregulated the expression of genes involved in lipid metabolism. Pathway enrichment analysis identified the activation of pathways involved in fatty acids and lipid biosynthesis and degradation in non-lesional skin and ferroptosis in plaque skin. VEGF-A inhibition downregulated endothelial cell apoptosis in non-lesional psoriasis skin and members of the interferon family were identified as potential regulators of the effects of VEGF-A inhibition in non-lesional skin.</p><p><strong>Conclusion: </strong>Early response to VEGF-A inhibition is associated with changes in lipid metabolism in non-lesional psoriasis skin and cellular stress in psoriasis plaque. More investigation is needed to validate these findings.</p>","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"4 6","pages":"e471"},"PeriodicalIF":0.0,"publicationDate":"2024-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11608907/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142775413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accuracy and confidence of Irish general practitioners in diagnosing skin disease in patients with darkly pigmented skin.","authors":"Rachel Rey, Eileen Duggan, Cathal O'Connor","doi":"10.1002/ski2.465","DOIUrl":"https://doi.org/10.1002/ski2.465","url":null,"abstract":"<p><p>Managing skin conditions in patients with darkly pigmented skin (DPS) can be challenging due to inadequate exposure to dermatology in DPS in clinical training. In this study, Irish GPs were less likely to correctly diagnose common skin conditions in patients with DPS (<i>p</i> < 0.001) and had lower confidence levels in diagnosis in DPS (<i>p</i> < 0.001). Lower diagnostic accuracy and confidence with common skin conditions in DPS in primary care may lead to misdiagnosis, suboptimal treatment and increased referrals to dermatology.</p>","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"4 6","pages":"e465"},"PeriodicalIF":0.0,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11608903/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142775346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Need of a revised and succinct atopic dermatitis diagnostic criteria for busy outpatient department in Nepalese context.","authors":"Prajwal Pudasaini, Sagar Gc, Mauricio Salas-Garza","doi":"10.1002/ski2.468","DOIUrl":"https://doi.org/10.1002/ski2.468","url":null,"abstract":"","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"4 6","pages":"e468"},"PeriodicalIF":0.0,"publicationDate":"2024-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11608898/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142775389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and efficacy of the swift microwave device in patients with mild-to-moderate onychomycosis: Protocol of an open-label, randomized, dose-finding pilot study.","authors":"Aditya K Gupta, Elizabeth A Cooper, Tong Wang","doi":"10.1002/ski2.455","DOIUrl":"https://doi.org/10.1002/ski2.455","url":null,"abstract":"<p><strong>Background: </strong>Onychomycosis is a common fungal nail disease with a prevalence rate up to 14% in North America and 24% in Europe. The current treatment paradigm is limited by a high risk of disease recurrence, safety concerns for oral agents, and a low likelihood of patients achieving both clinical improvement and mycological cure. Recent advances in device-based treatments have allowed for the direct targeting of the infection site that bypasses drug resistance mechanisms while minimizing systemic side-effects. The Swift^® System is a microwave device that has demonstrated therapeutic potential in treating skin (e.g. verrucae vulgaris, actinic keratosis) and nail infections.</p><p><strong>Methods: </strong>We report the protocol of an open-label, randomized, pilot study that will be conducted at a single Canadian center. Our primary objective is to evaluate the safety and efficacy of microwave treatment (Swift^® System, Emblation Ltd, Scotland, U.K.), administered at three different dosing regimens, in 45 patients with mild-to-moderate distal subungual onychomycosis. Our secondary objective is to identify an optimal dosing regimen, if any, to better inform the conduct of a future pivotal trial. Patients will be randomized (1:1:1) to undergo either 9 treatment sessions (5 weekly sessions plus 4 monthly sessions), 7 treatment sessions (3 sessions every 2 weeks plus 4 monthly sessions), or 12 treatment sessions every 2 weeks. At each session microwave energy will be applied in 3-s intervals at 7-9 Watts, repeated up to 5 times at each treatment position on the nail. Overlapping treatment positions are used to ensure sufficient coverage of the infected area. Patients will be enrolled in the trial over a 12-month period. Efficacy will be evaluated based on visual improvement and mycology testing results. Adverse events will be recorded throughout the entire study period.</p><p><strong>Discussion: </strong>This study will be the first to report on the safety and efficacy of microwave treatment in onychomycosis patients in a trial setting; recruitment is ongoing.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov, NCT05674747.</p>","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"4 6","pages":"e455"},"PeriodicalIF":0.0,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11608870/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142775324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}